natgillin/translations-raw huggingface dataset:
The immunogenic composition of claim 1 or use of claim 2 wherein the medicament is to be administered with at least one additional antigen, further for use in treating or preventing at least one disease selected from the group consisting of tuberculosis, leprosy, Mycobacterium avium infection, non-tuberculosis mycobacterial infection, Buruli ulcer, Mycobacterium bovis infection or disease, smallpox, monkeypox, Mycobacterium paratuberculosis infection, inflammatory bowel disease, Crohns Disease, autoimmune disease, cancer and bladder cancer. 
Imunogena smjesa prema zahljevu 1 ili uporaba prema zahljevu 2, gdje se lijek primjenjuje s najmanje jednim dodatnim antigenom, dalje za uporabu u liječenju ili prevenciji najmanje jedne bolesti izabrane iz skupine koja obuhvaća tuberkulozu, lepru, zarazu s Mycobacterium avium, ne-tuberkuloznu mikobakterijsku zarazu, Buruli čir, zarazu ili bolest Mycobacterium bovis, male boginje, boginje majmuna, zarazu s Mycobacterium paratuberculosis, upalnu bolest crijeva, Crohnovu bolest, autoimunu bolest, rak i rak mjehura.
Zirconia in the metastable cubic phase (specific volume=0.16 cm3/g) which can transform into the monoclinic phase (specific volume=0.17 cm3/g) (volume ratio=1.046); 
Cirkonijev oksid u metastabilnoj kubičnoj fazi (specifični volumen = 0.16 cm*/g) koja se može transformirati u monoklinsku fazu (specifični volumen = 0.17 cm*/g) (volumni omjer = 1.046);
selecting said patient for treatment with a WEE1 inhibitor, wherein the level of the predictive biomarker from said patient sample is below that of the control sample; and administering a WEE 1 inhibitor to the selected patient. 
(c) odabir navedenog pacijenta za liječenje inhibitorom WEE], gdje je nivo prognostičkog biomarkera iz navedenog pacijentovog uzorka ispod onog u kontrolnom uzorku; i (d) primjenu inhibitora WEE 1 kod odabranog pacijenta.
Usage of the material for surface treatment according to the claims 12 or 13 is characterized by the fact that the material is spread in the layer of the thickness ranging from 0,4 to 2 mm, preferably from 0,7 to 11 mm. 
Uporaba materijala za obradu površina sukladno patentnim zahtjevima 12 ili 13 je naznačena time da je taj materijal nanesen u sloju debljine u opsegu od 0,4 do 2 mm, preporučljivo od 0,7 do 11 mm.
Cy is an optionally substituted group selected from aryl and heteroaryl; 
Cy je izborno supstituirana skupina odabrana od arila i heteroarila;
A compound of claim 8, wherein the compound is: 
Spoj iz patentnog zahtjeva 8, gdje spoj je: zN N=N.
The fusion protein according to claim 1 of SEQ ID NO. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što ima SEQ ID NO.
Buffer is oxygenated with 95% 02/5% CO2 for 10 min at 37° C. and pH is adjusted 7.4. 
Bufer se oksidira s 95% O2/5% CO, 10 minuta na 37 stupnjeva C i pH se adaptira s 7.4.
the composition is a powder, tablet, pill, or capsule; 
(1) pripravak je prašak, tableta, pilula ili kapsula;
The interval can be, for example, 5 minutes to 24 or 48 hours (the interval between PSD-95 administration and reperfusion, here as elsewhere in this application, being measured from initiating PSD-95 inhibitor administration to initiating reperfusion administration). 
Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je interval između primjene PSD-95 i reperfuzijske terapije 30 minuta do 6 sati, ili što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije.
The method of claim 1, wherein the cumulative total amount of histidine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine, and proline per unit volume in said medium is greater than 35 mM. 
Postupak prema Zahtjevu 1, što je spomenuta kumulativna ukupna količina histidina, izoleucina, leucina, metionina, fenilalanina, triptofana, tirozina i prolina po jedinici volumena u spomenutom mediju veća od približno 35 mM.
The AC-AC HVDC converter system according to claim 7, wherein the physical transformer unit comprises a core design with two wound limbs and two outer return limbs and an unwound centre limb for return flux 
Sustav pretvarača AC-AC HVDC prema zahtjevu 7, naznačen time što jedinica fizičkog transformatora sadrži konstrukciju jezgre s dva namotana kraka i dva vanjska povratna kraka i nenamotan središnji krak za povratni tok.
The process according to any one of Claims 1 to 5, wherein the amine component of the amine salt of the compound of formula (II) is N(R40)3, where each R40 is independently -H or C1-12alkyl, or two R40 groups together with the nitrogen to which they are attached form a 4 to 6-membered heterocyclic ring and the remaining R40 is -H or C1-12alkyl. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time što aminska komponenta soli amina spoja s formulom (II) je N(R")s, gdje je svaki R" neovisno -H ili C,_,palkil, ili dvije R*" skupine zajedno s dušikom na koji su spojene tvore 4 do 6-člani heterociklički prsten i preostali R" je -H ili C,_,,alkil.
The method for hair dyeing or bleaching according to claim 1, further comprising applying the foam of the mixed solution to all the hair. 
Postupak bojanja ili izbjeljivanja kose u skladu s patentnim zahtjevom 1, naznačen time, da se pomiješana otopina koja se izbacuje u obliku pjene utrljava u kosu.
outputting data slice packets of PLP from the data slice, the data slice packet including header; 
izlaz paketa podatkovnih komada koji imaju PLP podatke iz podatkovnog komada;
The system of 5, further comprising an additional sensor configured to monitor current provided to the solenoid of the flush valve. The system of 4, further comprising an additional sensor configured to monitor fluid pressure within the flow passage to determine if a blockage is present in an outflow conduit downstream of the fluid outlet. 
Sustav u skladu s patentnim zahtjevom 2, naznačen time što dodatno sadrži dodatni senzor, konfiguriran za praćenje struje kroz zavojnicu (28) elektromagnetskog ventila (10), ili konfiguriran za praćenje tlaka tekućine u putu protoka radi određivanja ima li blokade u izlaznom cjevovodu nizvodno od izlaza tekućine (20).
Ar1, Ar2 cannot both identically represent either a 4-pyridyl, an unsubstituted 2 or 3- thiophenyl, or a 3,4-dimethoxyphenyl or a 3,4,5-trimethoxyphenyl, 
Ar1, Ar2 ne mogu oba identično da predstavljaju ili 4-piridil, nesupstituirani 2 ili 3- tiofenil, ili 3,4-dimetoksifenil ili 3,4,5-trimetoksifenil, i i j su 1;
The composition of claim 28, characterized in that it further comprises at least one agent as a combination product for simultaneous, separate or sequential use, and wherein said agent is an anti-tumoral antibody. 
Pripravak iz patentnog zahtjeva 14, naznačen time da dalje sadrži jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest antitumorsko antitijelo.
a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof; 
inhibitorom monooksigenaze citohroma P450 ili njegovom farmaceutski prihvatljivom solju;
The Luminex assay may employ a Biorad or R and D Luminex Kit. 
Pokus u skladu s patentnim zahtjevom 9, naznačen time, da se u postupku Luminex koristi Biorad ili R i D Luminex Kit.
If the number of modifiable coefficients is less than the first threshold TSIG_1, there is undertaken, in the course of the aforementioned step C 20, the conventional entropy coding of the coefficients of the list E1. For this purpose, the sign of each non-zero coefficient of the list E1 is coded entropically. 
-c.1) akoje navedeni broj koeficijenata između prvog i posljednjeg koeficijenta koji nije nula uključujući prvi i zadnji koeficijent koji nije nula manji od prethodno definiranog praga (TSIG), znak prvog koeficijenta koji nije nula nije sakriven ali je sadržan u podacima navedene particije (Bi)
If said suction cup does not effectively adhere to the pouch, the latter is not able to flex to such an extent as to allow the entry of a sufficient quantity of air to allow its opening. 
Ako se navedena usisna čašice ne prilijepi učinkovito na vrećicu, vrećica se ne može saviti u tolikoj mjeri da omogući ulaz dovoljne količine zraka kako bi se omogućilo njeno otvaranje.
A compound of the formula (I) according to claim 1 characterized by a compound of the formula (II) 
Spoj formule (I) u skladu s patentni zahtjev 1, naznačen time što ga karakterizira spoj formule (II) [image]
The line parts are then placed with their contact surfaces against one another, such that the sealing means of both line parts form a liquid-tight seal. 
Dijelovi cijevi se tada postavljaju tak da njihove kontaktne površine budu jedna nasuprot drugoj, tako da sredstvo za brtvljenje oba dijela cijevi sačinjava nepropusnu brtvu.
Embodiment 52. The pharmaceutical composition for use according to any preceding embodiment wherein the crosslinked amine polymer has a proton binding capacity of at least 10 mmol/g and a chloride ion binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa kapacitetom vezanja protona od najmanje 10 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 10 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCI 1 63 mM ECI, pri pH 1,21 na 3TC.
The sealing member can be pinched during closing in order to be preconstrained to absorb initial plays and/or gaps. 
Element za brtvljenje može biti stiješnjen za vrijeme zatvaranja, da bi bio prednapregnut kako bi se uvukao u početne zračnosti i/ili pukotine.
represents a hydrogen atom or a C1-6 alkyl group; 
predstavlja atom vodika ili C1-6 alkilnu skupinu;
In a process for obtaining a mixture of trifluoroacetyl glatiramer acetate, wherein the mixture has a desired average molecular weight and wherein during the process a batch of a mixture of polypeptides, each of which consists of alanine, Y-benzyl glutamate, tyrosine and trifluoroacetyl lysine is deprotected with a solution of hydrobromic acid in acetic acid, the improvement comprising use of a solution of hydrobromic acid in acetic acid, which solution comprises less than 0.1% of free bromine. 
Postupak za dobivanje smjese trifluoracetil glatiramer acetata, naznačen time, da se za vrijeme postupka, šarži smjese polipeptida, od kojih se svaki sastoji od alanina, Y-benzil glutamata, tirozina i trifluoracetil lizina, skida zaštita otopinom bromovodične kiseline u octenoj kiselini, kod čega poboljšanje obuhvaća uporabu otopine bromovodične kiseline u octenoj kiselini, koja otopina sadrži manje od 1000 ppm nečistoća metalnim ionima i manje od 0,5% slobodnog broma.
The genetically modified dermal micro-organ of any one of 14-18, wherein said at least one recombinant gene product is naturally produced by an organ from which the dermal micro-organ is derived. 
Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahtjeva 1 - 3, naznačen time, da je najmanje jedan navedeni rekombinantni genski produkt prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound or salt of claim 1 . 
Farmaceutski pripravak naznačen time što sadrži farmaceutski prihvatljiv nosač 1 farmaceutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-13.
For ammonia caramel the requirement is that the colour intensity is within the range of 0.08-0.36. 
Za amonij karamelu uvjet je da intenzitet boje bude unutar opsega od 0,08-0,36.
The IL-17 antagonisit for use according to Claim 25, wherein the monoclonal antibody or monoclonal antibody fragment is pegylated. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 25, naznačen time, da monoklonsko antitijelo ili fragment monoklonskog antitijela je pegiliran.
A method for detecting plant seed contamination of normal fertile plant seeds among cytoplasmic male sterile plant seeds, of an inbred line of a sunflower (Helianthus annuus) plant crop having a cytoplasmic or nuclear-cytoplasmic system of male sterility, comprising the steps of: 
Postupak za otkrivanje kontaminacije biljnog sjemena s normalnim plodnim sjemenkama biljke među citoplazmatskim muškim sterilnim biljkama sjemena, od urođene linije biljnog usjeva koji ima citoplazmatski ili nuklear-citoplazmatski sustav muške sterilnosti, naznačen time da se sastoji od sljedećih koraka:
A process for the preparation of isoserine derivatives 
POSTUPAK PRIPRAVE DERIVATA IZOSERINA
The liquefied gas treatment system according to claim 5, wherein the boil-off gas supplied to the heat exchanger (21) is a boil-off gas compressed while passing through all of the plurality of compression means included in the compressor (13,13a,13b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što dodatno uključuje element za potrošnju otparenog plina, koji prima i upotrebljava otpareni plin, koji se komprimira prilikom prolaska kroz dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
Examples of such carriers are magnesium stearate, starch, lactose, sucrose, cellulose. 
Primjeri takvih nosača su magnezij stearat, škrob, laktoza, saharoza i celuloza.
The nutritional composition according to claim 1, wherein at least 35 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid. 
4. Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje je barem 35 tež.% palmitinske kiseline od ukupne palmitinske kiseline esterificirano na sn-2 položaju triglicerida.
In yet another aspect of the present invention the hydrogen content of said fluid corresponds to at least 0.001% by weight of the amount of said organic material to be treated, such as at least 0.01% by weight of the amount of said organic material to be treated, and preferably 0.1% by weight of the amount of said organic material to be treated, such as 0.2% by weight of the amount of said organic material to be treated, and even more preferably the hydrogen content of the fluid is at least 0.5% by weight of the amount of said organic material to be treated, such as at least 1% by weight of the amount of said organic material to be treated. 
Metoda u skladu s patentnim zahtjevom 42, pri čemu sadržaj vodika u navedenoj tekućini odgovara najmanje 0,001 % prema težini količine navedenog organskog materijala za tretiranje, kao što je najmanje 0,01 % prema težini navedenog organskog materijala za tretiranje, a poželjno 0,1 % prema težini navedenog organskog materijala za tretiranje, kao što je najmanje 0,2 % prema težini navedenog organskog materijala za tretiranje, a još poželjnije sadržaj vodika u tekućini je najmanje 0,5 % prema težini navedenog organskog materijala za tretiranje, kao što je najmanje 1 % prema težini navedenog organskog materijala za tretiranje.
A tablet according to claim 10, wherein the opioid hydrochloride salt comprises at least about 5% (by weight) of said core and said high molecular weight PEO comprises at least about 50% (by weight) of said core. 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji ima, bazirano na reološkim mjerenjima, približnu molekulsku masu od barem 1,000,00.
The method of claim 5, wherein Forward Error Correction encoding the L1 signaling data comprises: BCH encoding the L1 signaling data; 
Metoda iz patentnog zahtjeva 4, pri čemu FEC kodiranje signalnih podataka L1 obuhvaća: BCH kodiranje signalnih podataka razine 1;
In accordance with the present invention, IL-18BP to be purified may be native, i.e. 
Sukladno s ovim izumom, IL-18BP koji se pročišćava može biti nativan tj.
represents hydroxy, C1-C4 alkoxy or -NR10R11; R10 and R11 each independently represents hydrogen, methyl or ethyl. 
predstavlja hidroksi, C1- C4 alkoksi ili -NR10 R11; NR10 i R11 neovisno predstavlja vodik, metil ili etil.
A method of enhancing efficiency of downstream chromatography steps for purification of antibodies comprising: passing a composition comprising an antibody of interest and various contaminants through an ion exchange membrane, wherein the antibody and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the antibody to enhance the charge of the antibody and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the antibody and at least one contaminant; 
prikupljanja efluenta iz membrane za ionsku izmjenu koji sadrži željeno protutijelo; d. podvrgavanja efluenta membrane koji sadrži željeno protutijelo koraku kromatografije ionske izmjene sličnog naboja kao i prethodna membrana, i e. oporavka pročišćenog protutijela iz efluenta prema koraku kromatografije izmjene nabijenog iona.
wherein upon administration to the patient, release of the compound of Formula XXIII is sustained release; optionally wherein sustained release comprises a therapeutically effective amount of said compound of Formula XXIII in the blood stream of the patient for a period of at least about 36 hours after administration of the prodrug; 
Spoj za uporabu prema patentnom zahtjevu 17, naznačen time što produženo oslobađanje sadrži terapeutski efikasnu količinu navedenog spoja formule XXIII-V, XXIII-XVIII, XXIII-X ili XXIII-XIII u krvotoku pacijenta tijekom perioda od najmanje oko 36 sati nakon primjene spoja prema bilo kojem od patentnih zahtjeva 1 do 14.
The C6-C15-aromatic group can be substituted with 1-3 substituents or can be unsubstituted. 
C4-C,5-aromatska skupina može biti supstituirana s 1-3 supstituenta ili može biti nesupstituirana.
A capsule according to claim 11, wherein the height (HFR) of the further ridge (140) is larger than the height of the at least one projection (107). 
Kapsula (2) prema zahtjevu 21, naznačena time, da je visina dodatnog grebena (40) veća od visine grebena (28.i).
The formulation preferably also contain jojoba oil (Simmondsia Chinensis Oil) and/or shea butter (Butyrospermum Parkii Butter). 
Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, koja dalje sadrži ulje jojobe (ulje Simmondsia chinensis) i/ili shea maslac (maslac Butyrospermum parkii).
The method of claim 15, wherein the individual has a bleeding disorder. The method of claim 16, wherein the bleeding disorder is haemophilia. 
Modificirani serpin za uporabu prema zahtjevu 17, naznačen time, da pojedinac ima poremećaj s krvarenjem, dok se opcionalno kod poremećaja s krvarenjem radi o hemofiliji.
The present invention provides a compound of formula (I-M) wherein R1, R3 and R4 are all H. 
Spoj sukladno patentnom zahtjevu 6, formule (I-M): he G-AD; ž i ee, jeme i izborno gdje R', RŽ i R* su svi H.
THF, under nitrogen. The flask was placed in an ice/water/ammonium chloride, −13° C. bath. Solid lithium borohydride (29.0 mg, 1.331 mmol, 1.8 eq.) was charged to the reaction flask and the reaction stirred at −13° C. for two hours before raising the temperature to 0° C. The reaction was worked up after five hours fifteen minutes by diluting with EtOAc and washing with water and ammonium chloride solution. 
Tikvica je bila stavljena u kupelj led/voda/amonij klorid, temperature -13"%C, Kruti litij borhidrid (29.0 mg, 1.331 mmol, 1.8 ekv.) je bio stavljen u tikvicu za reakciju i reakcijska smjesa je bila miješana na -13*C dva sata prije porasta temperature na 0?C. Reakcijska smjesa je bila dorađena nakon pet sati 1 petnaest minuta razrjeđivanjem s EtOAc 1 ispirana s vodom i otopinom amonij klorida.
A still further object of the present invention is to provide a sheet for packaging food that can be manufactured cheaply with known systems and technologies. 
Također, daljnji cilj predloženog izuma je osigurati foliju za pakiranje hrane koja se može proizvesti jeftino s poznatim sistemima i tehnologijama.
A compound of formula (I) wherein: 
Spoj formule (I), kao što je prikazano niže:
The solid formulation according to claim 1 or 2, characterized in that the binder is selected from the group consisting of polyvidone/povidone, methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxymethylcellulose, starch and gelatine. 
Čvrsta formulacija prema patentnom zahtjevu 2 ili 3, naznačena time, da je vezivo odabrano iz skupine koja se sastoji od polividona/povidona, metilceluloze, hidroksipropilmetilceluloze (HPMC), hidroksimetilceluloze, škroba i želatine.
The composition according to claim 6, wherein said composition is in the form of a tablet. 
Kompozicija prema patentnom zahtjevu 12, za uporabu u liječenju dijabetesa tipa II ili pretilosti.
with a medium-strong to strong acid; and mixtures thereof. 
sa srednje jakom do jakom kiselinom; te njihove smjese.
The pharmaceutical composition for use according to claim 10, 11, 12 or 13, wherein the composition further comprises 0.1 µgto 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija za uporabu prema zahtjevu 22 naznačena time da navedeni farmaceutski pripravak nadalje sadrži 0.1 µg do 10 µg liksisenatida po jedinici inzulin glargina.
In some embodiments, the individual has received prior platinum-based chemotherapy and has a treatment-free interval for more than about any of 12, 18, 24, 36, or 48 months since the completion of the platinum-based chemotherapy. 
Pripravak ili kombinacija namijenjeni upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što je osoba prethodno primila kemoterapiju na bazi platine i ima interval bez liječenja dulji od otprilike 12 mjeseci nakon dovršenja kemoterapije na bazi platine.
The compound for use of claim 25, wherein the sleep disorder is a sleep-wake transition disorder, insomnia, restless legs syndrome, jet-lag, disturbed sleep, or a sleep disorder secondary to neurological disorders. 
Spoj za uporabu prema zahtjevu 25, naznačen time da je poremećaj spavanja poremećaj prelaska 12 sna u budnost, nesanica, sindrom nemirnih nogu, jet-lag, poremećaj spavanja, ili sekundarni poremećaj spavanja u vezi s neurološkim poremećajima.
mg Phosphoric acid 
Količina Fosforna kiselina
To an ice-cooled suspension of 3-fluoro-4-methanesulfonyl-benzaldehyde (1.3 g, 6.44 mmol) in ethanol (5 ml) under an inert atmosphere of Argon is added sodium borohydride (0.275 g, 7.27 mmol) portionwise over 2-3 minutes. 
U ledeno hladnu suspenziju 3-fluor-4-metansulfonil-benzaldehida (1,3 g, 6,44 mmolova) u etanolu (5 ml) pod inertnom atmosferom argona doda se natrijev borhidrid (0,275 g, 7,27 mmolova) u obrocima tijekom 2-3 minute.
The artemisinin compound for use according to claim 1, wherein the patient is suffering from diabetes type I, diabetes type 2, a C-peptide negative or C-peptide positive diabetes, or diabetes-associated disorders. 
Spoj artemizinina namijenjen upotrebi u skladu sa zahtjevom 1, naznačen time što pacijent boluje od dijabetesa tip 1, dijabetesa tip 2, dijabetesa negativnog na C-peptid ili dijabetesa pozitivnog na C-peptid, ili od poremećaja povezanih s dijabetesom.
a unit for scrubbing with water and for fractionation of the gas stream in order to divide the stream of synthesis gas into at least two effluents; 
* jedinicu za kondicioniranje sinteznog plina, koja sadrži: * jedinicu za ispiranje s vodom i za frakcioniranje struje plina kako bi se podijelila struja sinteznog plina u barem dva efluenta;
substitution of amino acid 839 to glycine. 
supstituciju aminokiseline 839 glicinom.
Number of protein atoms 
Broj međunarodne prijave:
A thiazole derivative represented by the formula (IC) or a pharmaceutically acceptable salt thereof for use in the treatment and/or prophylaxis of a mood disorder selected from major depression, dysthymia, a depression-related syndrome, a symptom of depression due to a physical disorder and a drug-induced symptom of depression. 
SM Oron g N (IC) ili njegova farmaceutski prihvatljiva sol, te time, da se upotrebljava za liječenje i/ili profilaksu poremećaja raspoloženja odabranog od osnovne jake depresije, distimije, sindroma povezanog s depresijom, simptoma depresije na temelju fizičkog poremećaja i simptoma depresije izazvanog supstancom.